GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » Total Current Liabilities

Ambrx Biopharma (Ambrx Biopharma) Total Current Liabilities : $18.18 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Ambrx Biopharma's total current liabilities for the quarter that ended in Jun. 2023 was $18.18

Ambrx Biopharma Total Current Liabilities Historical Data

The historical data trend for Ambrx Biopharma's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambrx Biopharma Total Current Liabilities Chart

Ambrx Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Current Liabilities
14.94 13.26 24.58 16.66

Ambrx Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Current Liabilities Get a 7-Day Free Trial 17.48 24.58 25.74 16.66 18.18

Ambrx Biopharma Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Ambrx Biopharma's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=11.025+1.734
+Other Current Liabilities+Current Deferred Liabilities
=3.494+0.407
=16.66

Ambrx Biopharma's Total Current Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=12.994+1.854
+Other Current Liabilities+Current Deferred Liabilities
=2.924+0.407
=18.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Ambrx Biopharma Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ambrx Biopharma (Ambrx Biopharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » Total Current Liabilities
Comparable Companies
INBX PHVS RVNC COGT ADPT KYMR NVAX IMTX PRME RGNX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
AMAM:USA
Address
10975 North Torrey Pines Road, La Jolla, CA, USA, 92037
Website
https://www.ambrx.com
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
Executives
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor director, officer: President and CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan 10 percent owner WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd. 10 percent owner C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg director C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans director C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando officer: Chief Operating Officer C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116

Ambrx Biopharma (Ambrx Biopharma) Headlines

From GuruFocus

Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (?50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments

By Marketwired • 10-23-2023

AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholders

By Business Wire • 01-08-2024

Cormorant Asset Management, LP Boosts Stake in Ambrx Biopharma Inc

By GuruFocus Research • 09-20-2023

Shareholder Alert: Ademi LLP investigates whether Ambrx Biopharma, Inc. has obtained a Fair Price in its transaction with Johnson & Johnson

By PRNewswire • 01-08-2024

Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences

By Marketwired • 09-05-2023

Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences

By sperokesalga sperokesalga • 05-11-2023

Ambrx to Present at Multiple Upcoming Investor Meetings

By sperokesalga sperokesalga • 05-30-2023

ACE-Breast-02 Pivotal Phase 3 Study of Ambrx's ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results

By Business Wire Business Wire • 03-01-2023

Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting

By sperokesalga sperokesalga • 03-27-2023

Ambrx Announces $75 Million Market Priced Registered Offering

By sperokesalga sperokesalga • 05-24-2023